	US 12,138,240 B2
	Treatment of cardiac dysfunction
Christopher U. Missling, New York, NY (US)
Assigned to Anavex Life Sciences Corp., , NY (US)
Filed by Anavex Life Sciences Corp., New York, NY (US)
Filed on Jul. 26, 2021, as Appl. No. 17/385,660.
Application 17/385,660 is a division of application No. 16/166,732, filed on Oct. 22, 2018, granted, now 11,071,723.
Claims priority of provisional application 62/574,913, filed on Oct. 20, 2017.
Prior Publication US 2022/0096424 A1, Mar. 31, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/34 (2006.01); A61K 31/341 (2006.01); A61P 9/00 (2006.01); A61P 9/06 (2006.01)

CPC A61K 31/34 (2013.01) [A61K 31/341 (2013.01); A61P 9/00 (2018.01); A61P 9/06 (2018.01)]

16 Claims

1. A method for treating a cardiac dysfunction, comprising administering to a subject in need thereof a therapeutically effective amount of ANAVEX 19-144, a pharmaceutically acceptable salt thereof, or a combination of ANAVEX 19-144 or a pharmaceutically acceptable salt thereof with ANAVEX 2-73;

wherein the subject's QT interval is shortened by the shorter of about 10 ms (milliseconds) and by about 2% to about 3%, relative to the subject's QT interval before the administration; and

wherein the QT interval is a measure of time between the start of the Q wave and the end of the T wave in the heart's electrical cycle.